Abstract
BRAF is a serine/threonine kinase that receives a mitogenic signal from RAS and transmits it to the MAP kinase pathway. Recent studies have reported that mutations of the BRAF gene were detected with varying frequencies in several cancers, notably more than 60% in melanoma. We analysed mutations of BRAF and RAS genes in 100 cases of thyroid carcinoma to investigate genetic aberrations in the RAS/RAF/MEK/MAP kinase pathway. BRAF mutations were detected exclusively in papillary carcinomas (40 in 76 cases: 53%), and were exclusively V599E, a mutation frequently observed in other carcinomas. NRAS mutation was observed in six cases (6%), all in histological types other than papillary carcinoma, and was exclusively Q61R. No mutations were found in KRAS or HRAS. Our results suggest that BRAF mutations may play a critical role in the carcinogenesis of papillary carcinoma of the thyroid.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- BRAF:
-
v-raf murine sarcoma viral oncogene homologe B1
- MAP kinase:
-
mitogen-activated protein kinase
- MEK kinase:
-
mitogen-activated protein kinase kinase
References
Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP and Ballotti R . (2000). EMBO J., 19, 2900–2910.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA. (2002). Nature, 417, 949–954.
Halaban R . (2000). Pigment Cell Res., 13, 4–14.
Lazzereschi D, Minicione G, Coppa A, Ranieri A, Turco A, Baccheschi G, Pelicano S and Colletta G. . (1997). J. Exp. Clin. Cancer Res., 16, 325–332.
Learoyd DL, Messian M, Zedenius J and Robinson BG . (2000). World J. Surg., 24, 923–933.
Ledent C, Parmentier M, Maenhaut C, Taton M, Pirson I, Lamy F, Roger P and Dumont JE . (1991). Thyroidology, 3, 97–101.
Manenti G, Pilotti S, Re FC, Della Porta G and Pierotti MA . (1994). Eur. J. Cancer, 30, 987–993.
Naoki K, Chen TH, Richards WG, Sugarbaker DJ and Meyerson M . (2002). Cancer Res., 62, 7001–7003.
Pierotti MA, Bongarzone I, Borello MG, Greco A, Pilotti S and Sozzi G . (1996). Genes Chromosom. Cancer, 16, 1–14.
Sebolt-Leopold JS . (2000). Oncogene, 27, 6594–6599.
Sugg SL, Ezzat S, Zheng L, Freeman JL, Rosen IB and Asa SL . (1999). Surgery, 125, 46–52.
Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY . (2002). Cancer Res., 62, 6451–6455.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fukushima, T., Suzuki, S., Mashiko, M. et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22, 6455–6457 (2003). https://doi.org/10.1038/sj.onc.1206739
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206739
Keywords
This article is cited by
-
Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1
International Journal of Clinical Oncology (2024)
-
Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection
European Journal of Nuclear Medicine and Molecular Imaging (2022)
-
Defining and Targeting BRAF Mutations in Solid Tumors
Current Treatment Options in Oncology (2021)
-
Polymorphisms of IL-4 and IL-4R are associated to some demographic characteristics of differentiated thyroid cancer patients but are not determinants of risk in the Brazilian population
Endocrine (2021)
-
Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
BMC Cancer (2020)